{"entity":{"id":"paper-liu-geneplus-personalised-mrd-medcomm-2025","kind":"paper","name":"Personalized and Tumor Informed Circulating Tumor DNA Assay for Molecular Residual Disease Monitoring of Solid Malignancies","aka":[],"tldr":"Geneplus' personalised blood test found relapse months before scans in bowel, breast and lung cancer, and the mutations shared by every tumour cell were the most informative.","summary":"The assay profiles the tumour with a comprehensive genomic panel, selects up to 20 top-ranked variants for a personalised panel and integrates it with a tumour-naive cancer-type fixed panel for ultra-deep plasma sequencing. Its sample-level limit of detection reaches as low as 0.005 per cent with 100 per cent specificity. In colorectal, breast and lung cancer it predicted postoperative recurrence before imaging by a median of 112 days in breast and 83 days in lung cancer. Among tracked variants, clonal mutations showed more prognostic value than subclonal ones.","asOf":"2026-11-04","links":[{"label":"Liu et al., MedComm 2025","url":"https://doi.org/10.1002/mco2.70483"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/41346570/"}],"tags":[],"related":[],"cancers":["colorectal","breast-cancer","nsclc"],"sections":["diagnostics"],"technologies":["mrd-testing"],"targets":[],"drugs":["geneplus-personalised-mrd"],"companies":["geneplus"],"institutions":[],"pathways":[],"terms":["mrd","ctdna","tumour-informed-assay"],"trials":[],"people":[],"bottlenecks":["b-subclone-attribution-residual-disease"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"journal":"MedComm","year":2025,"doi":"10.1002/mco2.70483","pmid":"41346570","authors":"Liu L, Liang W, Cao W, et al.","paperType":"methods","findings":["Sample-level limit of detection 0.005%, specificity 100%.","Lead time 112 days (breast), 83 days (lung).","Clonal variants more prognostic than subclonal."],"whatItMeans":"Subclonal variants are seen less often in residual disease than clonal ones, which is what limits attributing what is left to a subclone.","caveats":["Company co-authored."]},"route":"/key-papers/paper-liu-geneplus-personalised-mrd-medcomm-2025/","neighbours":{"cancer":[{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/"},{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"section":[{"id":"diagnostics","kind":"section","name":"Diagnostics & Biomarkers","route":"/fronts/diagnostics/"}],"technology":[{"id":"mrd-testing","kind":"technology","name":"MRD / molecular residual disease testing","route":"/technologies/mrd-testing/"}],"drug":[{"id":"geneplus-personalised-mrd","kind":"drug","name":"Geneplus personalised MRD assay","route":"/drugs/geneplus-personalised-mrd/"}],"company":[{"id":"geneplus","kind":"company","name":"Geneplus-Beijing","route":"/companies/geneplus/"}],"term":[{"id":"ctdna","kind":"term","name":"Circulating tumour DNA (ctDNA)","route":"/terms/ctdna/"},{"id":"mrd","kind":"term","name":"Minimal / molecular residual disease (MRD)","route":"/terms/mrd/"},{"id":"tumour-informed-assay","kind":"term","name":"Tumour-informed versus tumour-naive ctDNA assays","route":"/terms/tumour-informed-assay/"}],"bottleneck":[{"id":"b-subclone-attribution-residual-disease","kind":"bottleneck","name":"Naming which clone or phenotype is left after treatment","route":"/bottlenecks/b-subclone-attribution-residual-disease/"}]}}